Some diseases exist because a single gene does not work the way it should. A mutation might mean a protein never gets made, gets made incorrectly, or gets made in the wrong amount entirely. Gene therapy approaches this problem directly, working at the genetic level rather than only managing the symptoms that result from it. The field’s path from theory to approved medicine has been long and, at points, genuinely dangerous: the first gene therapy clinical trial took place in 1990, and the field suffered a major setback in 1999 when a teenage patient named Jesse Gelsinger died during a clinical trial due to an immune reaction to the viral vector used, a tragedy that halted much of the field’s momentum for nearly a decade while researchers rebuilt safety protocols from the ground up.
That difficult history makes the field’s current momentum all the more notable. The FDA has now approved dozens of individual cell and gene therapy products, and the agency’s own projections, issued back in 2019, anticipated approving 10 to 20 new cell and gene therapy products annually by 2025, a pace the field has largely tracked. The global gene therapy market, valued at roughly $7 billion in 2022, is projected by multiple industry analyses to exceed $30 billion by 2030, reflecting both genuine scientific progress and the enormous cost of bringing each individual therapy through clinical trials and into regulatory approval.
Not every disease traces back to a single defective gene, which means gene therapy is not a universal solution to genetic disease broadly. It is a set of specific technologies, each suited to particular kinds of genetic problems, and the field’s progress reflects how well those technologies have been matched to specific diseases over time.
The Basic Idea: Treating Disease at the Genetic Level
Genes contain instructions for building proteins, and mutations can disrupt those instructions in different ways: some mutations cause a gene to stop working entirely, others cause a protein to function abnormally, and others cause a gene to become overactive when it should not be. Somatic gene therapy targets genes within a patient’s existing cells to treat disease during their lifetime, and it is distinct from heritable genetic modification, which would alter genes passed on to future generations.
Currently approved gene therapies are somatic, affecting only the treated individual; germline editing in humans remains prohibited or tightly restricted in the large majority of countries following the international controversy that erupted after a Chinese researcher controversially claimed to have created gene-edited babies in 2018, an act widely condemned by the global scientific community.
Four Major Ways Gene Therapy Can Work
Gene replacement or supplementation
This approach supplies a functional copy of a gene to compensate for one that is missing or not working properly, commonly used for conditions caused by a single non-functional gene, such as the SMN1 gene replacement used in Zolgensma for spinal muscular atrophy.
Gene editing
Gene editing technologies make targeted modifications directly to a patient’s existing DNA sequence, correcting or disabling specific genetic sequences at their source rather than adding an entirely new gene copy. CRISPR-Cas9, the gene editing technology behind Casgevy, the first CRISPR-based therapy to reach FDA approval in December 2023, earned its discoverers, Jennifer Doudna and Emmanuelle Charpentier, the 2020 Nobel Prize in Chemistry, a remarkably fast turnaround from basic discovery in 2012 to a Nobel Prize and an approved medicine within roughly a decade.
Gene silencing or regulation
Some therapies work by reducing the activity of a harmful gene rather than replacing or editing it, useful for conditions caused by a gene that is overactive or produces a toxic product.
Genetically modified cells
This approach modifies cells outside the body, commonly immune cells or blood-forming stem cells, before returning them to the patient. CAR T-cell therapy, where immune cells are engineered to better recognize cancer cells, is a widely known example of this category, with the first CAR T-cell therapy approved by the FDA in 2017 and more than a half-dozen distinct CAR T products now approved for various blood cancers.
How Does Genetic Material Reach the Right Cells?
Viral vectors, meaning modified viruses stripped of their disease-causing capability and repurposed to deliver genetic material, are the most common delivery method. Adeno-associated virus, or AAV, vectors are used in the majority of approved in vivo gene therapies specifically because they trigger a relatively mild immune response and can target specific tissue types effectively. Nonviral delivery methods, including lipid nanoparticles, the same delivery technology that carried mRNA COVID-19 vaccines into cells, offer an alternative approach with different advantages and limitations.
Tissue targeting matters enormously, since a therapy needs to reach the specific cells where the genetic correction will actually make a clinical difference. In vivo treatment delivers genetic material directly into the patient’s body, while ex vivo treatment modifies cells outside the body before reinfusion. Delivery remains one of the central engineering challenges in the field, since getting genetic material efficiently and safely into the right cells, and only the right cells, is far harder than it sounds; manufacturing a single batch of an ex vivo cell therapy for one patient can take several weeks and involve dozens of individual quality control checkpoints before the modified cells are cleared for reinfusion.
From Laboratory Concept to Approved Therapy
Discovery research identifies a genetic mechanism and a potential therapeutic strategy. Preclinical studies test safety and initial efficacy in laboratory and animal models. Clinical trials then test the therapy in human patients across multiple phases, evaluating safety first and effectiveness afterward. Manufacturing at clinical and commercial scale presents its own significant challenges, particularly for therapies involving personalized cell modification; some ex vivo gene therapies can only be manufactured at one or two specialized facilities worldwide, creating real bottlenecks in how quickly eligible patients can actually be treated even after approval.
Regulatory review by the FDA evaluates the accumulated evidence before a therapy can be marketed, and post-approval monitoring continues to track safety and long-term outcomes even after a therapy reaches patients, often through mandatory long-term follow-up studies extending 10 to 15 years given the theoretical risk of delayed effects from permanently altering a patient’s genetic material. The FDA’s growing list of approved cellular and gene therapy products shows that this pathway, while lengthy, has produced a real and expanding set of clinically available treatments.
What Gene Therapy Can Offer Patients
Some approved gene therapies have demonstrated long-lasting effects from a single treatment, offering the potential to address previously difficult-to-treat conditions by targeting their underlying biological mechanism directly. For certain diseases, this could mean a reduced burden of repeated treatments compared to older management approaches; patients with hemophilia B, for instance, have historically required infusions multiple times per week for life, a burden that clinical trial data for Hemgenix suggests a single gene therapy treatment can eliminate for at least eight years and potentially much longer based on ongoing follow-up.
These represent potential outcomes rather than guarantees. Not every gene therapy delivers permanent benefit, and outcomes vary considerably by disease, by specific therapy, and by individual patient factors that are not always fully understood even after a therapy is approved.
The Risks and Scientific Challenges
Immune reactions to the vector or the newly expressed protein represent a real safety concern for many gene therapies, a risk directly linked to the field’s early history and one that has driven considerable investment in developing gentler, more targeted vector systems over the past two decades. Delivery limitations mean some tissues remain difficult to target effectively. Off-target effects, where a gene editing tool modifies unintended parts of the genome, remain a relevant consideration for gene editing approaches specifically, and extensive preclinical off-target screening is now a standard, heavily scrutinized part of any gene editing therapy’s regulatory review.
Manufacturing complexity, particularly for personalized cell-based therapies, affects both cost and availability. Durability of effect and the need for long-term monitoring add further complexity, since some therapies have not existed long enough to fully characterize decades-long outcomes. Cost and access represent practical barriers that affect which patients can realistically receive an approved therapy, even when eligibility criteria are met, with several currently approved therapies priced between $2 million and over $4 million per treatment. Risks differ significantly among therapies, so generalizing safety concerns across the entire field oversimplifies a genuinely varied picture.
Gene Therapy Versus Gene Editing
| Aspect | Gene therapy (broad term) | Gene editing (specific technique) |
|---|---|---|
| Scope | Umbrella term covering multiple approaches | One specific approach within gene therapy |
| Mechanism | May add, silence, or modify genetic material | Makes precise, targeted changes to existing DNA |
| Common use | Replacement therapies, cell-based therapies, editing-based therapies | A tool used within certain gene therapy applications |
| Public usage | Sometimes used interchangeably with gene editing in media | Technically a subset of gene therapy approaches |
The terms are frequently used interchangeably in popular media, but gene editing describes a specific technique, while gene therapy is the broader category that includes gene editing alongside other approaches like gene replacement and cell-based therapies.
Where the Field Is Going Next
More precise, tissue-specific delivery methods, newer generations of gene editing technology, expansion into a broader range of rare diseases, continued development in cancer applications, combination therapies that pair gene therapy with other treatment modalities, and improved manufacturing processes that could reduce cost and expand access all represent active directions of development. Several hundred gene and cell therapy candidates are currently in active clinical trials worldwide according to industry pipeline trackers, suggesting the pace of new approvals seen over the past several years is likely to continue rather than slow down.
Meaningful uncertainty remains about which specific research directions will translate into approved therapies and on what timeline. Honest assessment of this uncertainty is more useful to patients and families than presenting every promising laboratory finding as an imminent clinical breakthrough.
Gene therapy is best understood as a family of related technologies rather than a single treatment, one that has traveled an unusually difficult path from a devastating early setback in 1999 to a genuinely transformative present, in which patients with diseases that had no meaningful treatment options a generation ago can now, in specific and well-defined circumstances, receive a single treatment with the potential for lasting benefit. What gene therapy actually means for a specific patient depends on the therapeutic approach involved, the disease being treated, the strength of the supporting evidence, and the specific eligibility criteria that apply, not on general enthusiasm about the field’s overall progress.
This article provides general educational information and does not constitute medical advice or a treatment recommendation.
FAQ
Q: What is gene therapy in simple terms?
A: It is a treatment approach that works directly at the genetic level, adding, editing, silencing, or otherwise modifying genes to address the underlying cause of certain diseases.
Q: How does gene therapy work?
A: Depending on the approach, it may supply a functional gene copy, edit existing DNA, reduce the activity of a harmful gene, or use genetically modified cells to fight disease.
Q: Is gene therapy the same as gene editing?
A: No. Gene editing, such as CRISPR, is one specific technique within the broader category of gene therapy, which also includes gene replacement and cell-based approaches.
Q: Is gene therapy permanent?
A: Some therapies have shown durable, long-lasting effects tracked past five years in certain cases, but permanence varies by disease and specific therapy, and long-term data for many newer treatments is still developing.
Q: What diseases can gene therapy treat?
A: Currently approved uses include certain inherited blood disorders, rare genetic diseases, inherited eye conditions, hemophilia, and several blood cancers.
Q: What are the risks of gene therapy?
A: Risks vary by therapy and can include immune reactions, delivery limitations, manufacturing complexity, and in some cases, longer-term effects still under study.
Q: Is gene therapy safe?
A: Approved gene therapies have passed through clinical trials evaluating safety and efficacy, though risks differ by therapy and ongoing monitoring continues after approval, often for a decade or more.
Q: Is gene therapy available to everyone?
A: No. Eligibility is highly specific to each approved therapy and depends on confirmed diagnosis, disease severity, prior treatment, and other clinical factors, and treatment access is further limited by cost and manufacturing capacity.